J
Jeffrey M. Karp
Researcher at Brigham and Women's Hospital
Publications - 286
Citations - 26189
Jeffrey M. Karp is an academic researcher from Brigham and Women's Hospital. The author has contributed to research in topics: Mesenchymal stem cell & Stem cell. The author has an hindex of 58, co-authored 278 publications receiving 22236 citations. Previous affiliations of Jeffrey M. Karp include Massachusetts Institute of Technology & University of Minnesota.
Papers
More filters
Journal ArticleDOI
Nanocarriers as an emerging platform for cancer therapy
Dan Peer,Jeffrey M. Karp,Jeffrey M. Karp,Seungpyo Hong,Omid C. Farokhzad,Rimona Margalit,Robert Langer +6 more
TL;DR: The arsenal of nanocarriers and molecules available for selective tumour targeting, and the challenges in cancer treatment are detailed and emphasized.
Journal ArticleDOI
Progress and challenges towards targeted delivery of cancer therapeutics.
TL;DR: The principles behind targeted delivery approaches are reviewed to determine potential reasons for their limited clinical translation and success and criteria and considerations that must be taken into account for the development of novel actively targeted NCs are proposed.
Journal ArticleDOI
Mesenchymal Stem Cell Homing: The Devil Is in the Details
TL;DR: A critical analysis of the methods used to track homing of exogenously infused MSCs is provided and strategies for enhancing their trafficking to particular tissues are discussed.
Journal ArticleDOI
Mesenchymal stem cells: immune evasive, not immune privileged
TL;DR: Protecting MSCs from immune detection and prolonging their persistence in vivo may improve clinical outcomes and prevent patient sensitization toward donor antigens.
Journal ArticleDOI
Harnessing the mesenchymal stem cell secretome for the treatment of cardiovascular disease.
Sudhir H. Ranganath,Oren Levy,Oren Levy,Oren Levy,Maneesha S. Inamdar,Maneesha S. Inamdar,Jeffrey M. Karp,Jeffrey M. Karp,Jeffrey M. Karp +8 more
TL;DR: The current understanding of the MSC secretome as a therapeutic for treatment of ischemic heart disease is outlined and ongoing investigative directions aimed at improving cellular activity and characterizing the secretome and its regulation are discussed.